Evidence map›Paper›PMID 41057324›Full record

ArticleNature communications2025

Accessing acyclic vicinal tetrasubstituted stereocenters via biomimetic Cu/squaramide cooperative catalysed asymmetric Mannich reactions.

Wen-Run Zhu, Ze-Long Ouyang, Xuzhao Du, Yun-Zhe Li, Xiao-Yi Deng, Yu-Jie Xue, Jian-Xin Zhou, Peiyuan Yu, Gui Lu, Albert S C Chan and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wen-Run Zhu *State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China.ORCID http://orcid.org/0009-0003-4257-7596
Ze-Long Ouyang *State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China.
Xuzhao Du *Department of Chemistry and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, P. R. China.
Yun-Zhe Li *State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China.
Xiao-Yi DengState Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China.ORCID http://orcid.org/0000-0001-6057-9032
Yu-Jie XueSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, P.R. China.
Jian-Xin ZhouSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, P.R. China.
Peiyuan YuDepartment of Chemistry and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, P. R. China. yupy@sustech.edu.cn.ORCID http://orcid.org/0000-0002-4367-6866
Gui LuState Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China. lugui@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-0089-0907
Albert S C ChanState Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China.
Jiang WengState Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, P. R. China. wengj2@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-4117-4686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The catalytic asymmetric Mannich reaction offers efficient approaches for the simultaneous construction of a C-C bond and two adjacent stereocenters in a single step. However, employing the Mannich reaction to create two neighboring, fully substituted carbon stereocenters in acyclic systems presents significant challenges and remains largely unexplored. Inspired by class II aldolases found in nature, we report here a biomimetic copper/squaramide cooperative catalysis strategy for asymmetric Mannich reactions between challenging acyclic ketimines and α-substituted β-keto esters. The highly functionalized Mannich adducts featuring vicinal and acyclic tetrasubstituted stereocenters are obtained, and exhibit good yields and excellent stereoselectivities (up to >19:1 dr and 99% ee). The versatile utility of these enantioenriched products is further highlighted by their diverse transformations with complete diastereocontrol. Mechanistic studies and DFT calculations support the novel cooperative roles of copper and squaramide in substrate activation and stereoselectivity control.

Identifiers

PMID41057324
PMCPMC12504757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.